Janet H Ford

6PUBLICATIONS
9CO-AUTHORS
Molecular medicineGlycoconjugatesTraditional Chinese medicine and treatmentsMicroelectromechanical systems (MEMS)Health psychology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Aug 02, 2025
Patient Preferences for Self-Injectable Preventive Treatment for Migraine: A Multi-country Discrete Choice Experiment.

Jaein Seo, Caitlin Thomas, Tommi Tervonen

|Feb 16, 2023
Changes in migraine interictal burden following treatment with galcanezumab: Results from a phase III randomized, placebo-controlled study.

Richard B Lipton, Dawn C Buse, Claire H Sandoe

|Mar 07, 2022
Correction to: Effects of Galcanezumab on Health-Related Quality of Life and Disability in Patients with Previous Failure of 2-4 Migraine Preventive Medication Categories: Results from a Phase IIIb Randomized, Placebo-Controlled, Multicenter Clinical Trial (CONQUER).

Stewart J Tepper, Jessica Ailani, Janet H Ford

|Jan 18, 2022
Effects of Galcanezumab on Health-Related Quality of Life and Disability in Patients with Previous Failure of 2-4 Migraine Preventive Medication Categories: Results from a Phase IIIb Randomized, Placebo-Controlled, Multicenter Clinical Trial (CONQUER).

Stewart J Tepper, Jessica Ailani, Janet H Ford

|Jan 22, 2021
Psychometric validation and meaningful within-patient change of the Migraine-Specific Quality of Life questionnaire version 2.1 electronic patient-reported outcome in patients with episodic and chronic migraine.

Rebecca M Speck, Ren Yu, Janet H Ford

|Nov 29, 2020
Migraine Headache Day Response Rates and the Implications to Patient Functioning: An Evaluation of 3 Randomized Phase 3 Clinical Trials of Galcanezumab in Patients With Migraine.

Janet H Ford, Tobias Kurth, Amaal J Starling

Pageof 1

Frequent Collaborators

2 joint publications

David W Ayer

2 joint publications

Martha D Port

1 joint publications

Rebecca M Speck

1 joint publications

Rohit Bhandari